The observation that HCC-NED organoids did not respond to the selective pan-TRK inhibitor larotrectinib, but were sensitive to entrectinib, a pan-TRK inhibitor with additional activity against the proto-oncogene kinase ROS1 and anaplastic lymphoma kinase (ALK)44 does not support the hypothesis that constitutive TRK activity was a main oncogenic driver in our case. This evidence concerns the gene NTRK1 and hepatocellular carcinoma.